Patients with metastatic breast cancer are the primary beneficiaries of Myocet. It is particularly useful for patients who have previously been treated with anthracyclines or those who are at high risk for cardiotoxicity. Myocet may also be considered for other types of cancer, depending on the clinical scenario and the oncologist's discretion.
